---
title: "Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286268941.md"
description: "Lake Street's Frank Takkinen has maintained a Buy rating on Stereotaxis (STXS) with a price target of $4.00. The analyst focuses on the Healthcare sector and has an average return of -1.2% with a 37.92% success rate on recommendations. The consensus on Stereotaxis is a Strong Buy, with an average price target of $4.13."
datetime: "2026-05-13T13:17:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286268941.md)
  - [en](https://longbridge.com/en/news/286268941.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286268941.md)
---

# Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Stereotaxis, with a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Takkinen covers the Healthcare sector, focusing on stocks such as Stereotaxis, LENSAR, and TriSalus Life Sciences. According to TipRanks, Takkinen has an average return of \-1.2% and a 37.92% success rate on recommended stocks.

Currently, the analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.13.

### Related Stocks

- [STXS.US](https://longbridge.com/en/quote/STXS.US.md)
- [LNSR.US](https://longbridge.com/en/quote/LNSR.US.md)
- [TLSI.US](https://longbridge.com/en/quote/TLSI.US.md)
- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [How investors can navigate the healthcare sector](https://longbridge.com/en/news/293960711.md)
- [University of Szeged Pioneers First Robotic Cardiology Program in Hungary | STXS Stock News](https://longbridge.com/en/news/293215157.md)
- [RBC Capital Sticks to Its Buy Rating for Axis Capital (AXS)](https://longbridge.com/en/news/294446630.md)
- [Analyst Initiates Buy on SGI, Citing Earnings Momentum, Consolidation Advantages and Re-Rating Upside Toward $95 Price Target](https://longbridge.com/en/news/293857355.md)
- [UnitedHealth Group Incorporated (NYSE:UNH) Given Consensus Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/294310676.md)